These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30385593)

  • 1. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus.
    Sobhy A; Fakhry M M; A Azeem H; Ashmawy AM; Omar Khalifa H
    J Investig Med; 2019 Mar; 67(3):681-685. PubMed ID: 30385593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B.
    Ciftciler R; Ozenirler S; Yucel AA; Cengiz M; Erkan G; Buyukdemirci E; Sönmez C; Esendaglı GY
    J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27925300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma.
    Lin CS; Chang CS; Yang SS; Yeh HZ; Lin CW
    Intern Med; 2008; 47(7):569-75. PubMed ID: 18379139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase.
    Zeng DW; Dong J; Jiang JJ; Zhu YY; Liu YR
    World J Gastroenterol; 2016 Nov; 22(43):9586-9594. PubMed ID: 27920479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive models for predicting histology in patients with chronic hepatitis B.
    Wai CT; Cheng CL; Wee A; Dan YY; Chan E; Chua W; Mak B; Oo AM; Lim SG
    Liver Int; 2006 Aug; 26(6):666-72. PubMed ID: 16842322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients.
    Karagoz E; Ulcay A; Tanoglu A; Kara M; Turhan V; Erdem H; Oncul O; Gorenek L
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1320-4. PubMed ID: 25210777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of non-invasive models of liver fibrosis in judgment of treatment timing in chronic hepatitis B patients with ALT < 2×upper limit of normal].
    Zhou QQ; Hu YB; Zhou K; Zhang WW; Li MH; Dong P; Di JG; Hong L; Du QW; Xie Y; Sun QF
    Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):665-670. PubMed ID: 27788722
    [No Abstract]   [Full Text] [Related]  

  • 8. [Lymphocyte subpopulations, levels of interferon, and expression of their receptors in patients with chronic hepatitis B and C: Correlation with the species of viruses and the degree of liver fibrosis].
    Kalyuzhin OV; Ponezheva ZB; Semenova IV; Khokhlova ON; Serebrovskaya LV; Guseva TS; Parshina OV; Maleev VV
    Ter Arkh; 2017; 89(11):14-20. PubMed ID: 29260741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive assessment of liver fibrosis in chronic viral hepatitis.
    Orasan OH; Iancu M; Sava M; Saplontai-Pop A; Cozma A; Sarlea ST; Lungoci C; Ungureanu MI; Negrean V; Sampelean D; Dumitrascu DL
    Eur J Clin Invest; 2015 Dec; 45(12):1243-51. PubMed ID: 26426402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C.
    Appourchaux K; Dokmak S; Resche-Rigon M; Treton X; Lapalus M; Gattolliat CH; Porchet E; Martinot-Peignoux M; Boyer N; Vidaud M; Bedossa P; Marcellin P; Bièche I; Estrabaud E; Asselah T
    Sci Rep; 2016 Oct; 6():34935. PubMed ID: 27731343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic hepatitis B and C.
    Öksüz Z; Üçbilek E; Serin MS; Yaraş S; Temel GO; Sezgin O
    Braz J Microbiol; 2020 Dec; 51(4):1757-1763. PubMed ID: 32959205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?
    Vardar R; Vardar E; Demiri S; Sayhan SE; Bayol U; Yildiz C; Postaci H
    Hepatogastroenterology; 2009; 56(94-95):1459-65. PubMed ID: 19950810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.
    Sturm N; Marlu A; Arvers P; Zarski JP; Leroy V
    Liver Int; 2013 Mar; 33(3):428-38. PubMed ID: 23402612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.
    Matsue Y; Tsutsumi M; Hayashi N; Saito T; Tsuchishima M; Toshikuni N; Arisawa T; George J
    PLoS One; 2015; 10(3):e0118744. PubMed ID: 25760884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The validity of serum markers for fibrosis staging in chronic hepatitis B and C.
    Li J; Gordon SC; Rupp LB; Zhang T; Boscarino JA; Vijayadeva V; Schmidt MA; Lu M;
    J Viral Hepat; 2014 Dec; 21(12):930-7. PubMed ID: 24472062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
    Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
    Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations.
    Tseng PL; Wang JH; Hung CH; Tung HD; Chen TM; Huang WS; Liu SL; Hu TH; Lee CM; Lu SN
    Kaohsiung J Med Sci; 2013 Jul; 29(7):385-95. PubMed ID: 23768703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
    Köksal İ; Yılmaz G; Parlak M; Demirdal T; Kınıklı S; Candan M; Kaya A; Akhan S; Aydoğdu Ö; Turgut H; Gürbüz Y; Dağlı Ö; Gökal AA; Güner R; Kuruüzüm Z; Tarakçı H; Beslen N; Erdoğan S; Özdener F; Study Group TCHC
    Turk J Gastroenterol; 2018 Jul; 29(4):464-472. PubMed ID: 30249562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C.
    Verveer C; Zondervan PE; ten Kate FJ; Hansen BE; Janssen HL; de Knegt RJ
    Liver Int; 2012 Apr; 32(4):622-8. PubMed ID: 22098684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.